| Guideline | Resources |
| Celiac Disease Dx and Mgmt: 2023 ACG Guidelines | epocrates Guideline Synopsis |
Key Points
Detection of celiac dz–specific Ab (e.g., TTG) is helpful for initial screening; intestinal bx is required in most pts to confirm dx. A non-bx strategy (TTG >10x ULN plus positive EMA in 2nd sample) may be used in selected children and adults unwilling/unable to undergo endoscopy.
Choose Patient Type
|
American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Am J Gastroenterol 2023;118:59-76.
Epocrates Guideline Synopsis Last Update:
May 4, 2023
Publication Year:
2023
Source:
ACG
- American College of Gastroenterology
Strength of Recommendation
| [S] | Strong recommendation |
| [C] | Conditional/discretionary/weak recommendation |
| [EvGap] | Evidence gap in recommendation |
Quality of Evidence
| [H] | High-quality evidence—further research unlikely to alter confidence about efficacy |
| [M] | Moderate-quality evidence—further research likely to affect future recommendations |
| [L] | Low-quality evidence—further research very likely to affect future recommendations |
| [VL] | Very low-quality evidence—any estimate of effect is very uncertain |
Abbreviations
| abd | abdominal |
| ALT | alanine aminotransferase |
| AST | aspartate aminotransferase |
| bx | biopsy |
| Cu | copper |
| DGP | deamidated gliadin peptides |
| DM | diabetes mellitus |
| DXA | dual-energy x-ray absorptiometry |
| EGD | esophagogastroduodenoscopy |
| EMA | endomysial antibody |
| Fe | iron |
| GFD | gluten-free diet |
| IBS | irritable bowel syndrome |
| IgA | immunoglobulin A |
| IgG | immunoglobulin G |
| QOL | quality of life |
| T1DM | type 1 diabetes mellitus |
| TTG | tissue transglutaminase |
| TTGA | tissue transglutaminase antibody |
| Zn | zinc |
Strength of Recommendation
| S | = | Strong recommendation |
| C | = | Conditional/discretionary/weak recommendation |
| EvGap | = | Evidence gap in recommendation |
Quality of Evidence
| H | = | High-quality evidence—further research unlikely to alter confidence about efficacy |
| M | = | Moderate-quality evidence—further research likely to affect future recommendations |
| L | = | Low-quality evidence—further research very likely to affect future recommendations |
| VL | = | Very low-quality evidence—any estimate of effect is very uncertain |